Head to Head Contrast: DiaMedica Therapeutics (NASDAQ:DMAC) versus Provectus Biopharmaceuticals (OTCMKTS:PVCT)

Provectus Biopharmaceuticals (OTCMKTS:PVCT) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Provectus Biopharmaceuticals and DiaMedica Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Provectus Biopharmaceuticals	0	0	0	0	N/A
DiaMedica Therapeutics	0	0	3	0	3.00

DiaMedica Therapeutics has a consensus price target of $7.00, indicating a potential upside of 64.71%. Given DiaMedica Therapeutics’ higher probable upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Provectus Biopharmaceuticals.

Earnings & Valuation

This table compares Provectus Biopharmaceuticals and DiaMedica Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Provectus Biopharmaceuticals	$560,000.00	81.20	-$3.10 million	N/A	N/A
DiaMedica Therapeutics	N/A	N/A	-$19.38 million	($0.53)	-8.02

Provectus Biopharmaceuticals has higher revenue and earnings than DiaMedica Therapeutics.

Risk and Volatility

Provectus Biopharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.

Profitability

This table compares Provectus Biopharmaceuticals and DiaMedica Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Provectus Biopharmaceuticals	-407.89%	N/A	-219.95%
DiaMedica Therapeutics	N/A	-38.56%	-36.46%

Insider & Institutional Ownership

0.1% of Provectus Biopharmaceuticals shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 12.8% of Provectus Biopharmaceuticals shares are owned by company insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

DiaMedica Therapeutics beats Provectus Biopharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.